Urinary markers for bladder cancer diagnosis: A review of current status and future challenges
International Journal of Urology · 2024-03 · 31 (3) · 208-219
DOI: 10.1111/iju.15338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Urology, online erschienen am 15.11.2023. Verfasst von Eisuke Tomiyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Urologic Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 98 Literaturangaben.
Abstract (Originalsprache)
Bladder cancer is a common urological cancer with a high recurrence rate that requires long‐term follow‐up, and early detection positively affects prognosis. To date, the initial diagnosis and follow‐up for bladder cancer rely on cystoscopy, which is an invasive and expensive procedure. Therefore, urinary markers for the detection of bladder cancer have attracted research attention for decades to reduce unnecessary cystoscopies. Urine, which is in continuous contact with bladder cancer, is considered a suitable fluid for providing tumor information. Urinary cytology is the only widely used urinary marker in clinical practice; however, it has poor sensitivity for low‐grade tumors; indicating the need for novel urinary markers. Considerable research has been conducted on this topic over the years, resulting in a complex landscape with a wide range of urinary markers, including protein‐, exfoliated cell‐, RNA‐, DNA‐, and extracellular vesicle‐based markers. Although some of these markers have been approved by the U.S. Food and Drug Administration and are commercially available, their use in clinical practice is limited. To facilitate clinical application, potential urinary markers must withstand prospective clinical trials and be easy for patients and clinicians to understand and utilize in a clinical context. This review provides a comprehensive overview of currently available and recently reported promising urinary markers for bladder cancer. Additionally, the challenges and the prospects of these urinary markers for clinical implementation in bladder cancer treatment were discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
ORCID-Profile: Eisuke Tomiyama, Kazutoshi Fujita, Mamoru Hashimoto, Hirotsugu Uemura
Zitieren
APA
Tomiyama, E., Fujita, K., Hashimoto, M., Uemura, H., & Nonomura, N. (2024). Urinary markers for bladder cancer diagnosis: A review of current status and future challenges. International Journal of Urology, 31(3), 208-219. https://doi.org/10.1111/iju.15338
Vancouver
Tomiyama E, Fujita K, Hashimoto M, Uemura H, Nonomura N. Urinary markers for bladder cancer diagnosis: A review of current status and future challenges. International Journal of Urology. 2024;31(3):208-219. doi:10.1111/iju.15338
BibTeX
@article{Tomiyama2024,
author = {Tomiyama, Eisuke and Fujita, Kazutoshi and Hashimoto, Mamoru and Uemura, Hirotsugu and Nonomura, Norio},
title = {Urinary markers for bladder cancer diagnosis: A review of current status and future challenges},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {3},
pages = {208--219},
doi = {10.1111/iju.15338}
}
EUVIMED